JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
James L. Cox
Niv Ad
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cox, J. L.
Right arrow Articles by Quijano, R.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cox, J. L.
Right arrow Articles by Quijano, R.C.
Related Collections
Right arrow Valve disease

J Thorac Cardiovasc Surg 2005;130:520-527
© 2005 The American Association for Thoracic Surgery

Surgery for Acquired Cardiovascular Disease

Tubular heart valves: A new tissue prosthesis design—Preclinical evaluation of the 3F aortic bioprosthesis

James L. Cox, MD a , * , Niv Ad, MD b , Keith Myers, BS c , Mortiz Gharib, PhD d , R.C. Quijano, MD, PhD c

a Division of Cardiothoracic Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St Louis, Mo
b Department of Cardiac Surgery, Hadassah School of Medicine, Jerusalem, Israel
c 3F Therapeutics, Inc, Lake Forest, Calif
d Department of Biomedical Engineering, California Institute of Technology, Pasadena, Calif.

Received for publication November 7, 2003; revisions received December 15, 2004; accepted for publication December 20, 2004.

* Address for reprints: James L. Cox, MD, Washington University School of Medicine, Suite 3108 Queeny Tower, Barnes-Jewish Hospital, One Barnes-Jewish Plaza, St Louis, MO 63110 (Email: jamescoxmd{at}aol.com).

BACKGROUND: It was hypothesized that native heart valves function as if they were simple tubes with sides that collapse when external pressure is applied. Because "form follows function," this hypothesis could theoretically be confirmed by implanting a simple tube into the anatomic position of any native heart valve and documenting that under the same anatomic constraints and physiologic conditions as the native valve, the tube would assume the form of that native valve. If the hypothesis were thus proved, it would follow that a tissue valve based on a tubular design would have superior flow dynamics and stress distribution and would therefore be expected to outlast currently available tissue valves. Such a tubular tissue valve, the 3F Aortic Bioprosthesis (3F Therapeutics, Inc, Lake Forest, Calif) was designed and tested in vitro against a commercially available stentless aortic bioprosthesis.

METHODS: With the use of state-of-the-art testing equipment, some of which had to be developed especially to test this truly stentless bioprosthesis in vitro, transvalvular gradients, effective orifice areas, degree of transvalvular laminar flow, finite element analysis of the distribution of leaflet stress, and accelerated wear testing for long-term durability were evaluated for the new 3F Aortic Bioprosthesis in comparison with the St Jude Medical Toronto SPV aortic bioprosthesis (St Jude Medical, Inc, St Paul, Minn).

RESULTS: The valve gradients were lower and the effective orifice areas were greater for the 3F Aortic Bioprosthesis at all valve sizes and under all test conditions, including cardiac outputs ranging from 2.0 to 7.0 L/min, mean perfusion pressures from 40 to 200 mm Hg, and aortic compliances of 4% and 16%. The transvalvular flow across the 3F Aortic Bioprosthesis in vitro was qualitatively smooth, with a minimum of surrounding vortices. Maximum stress occurred in the belly of the leaflets of the 3F Aortic Bioprosthesis, with minimum stress at the commissural posts. The 3F Aortic Bioprosthesis was superior to the Toronto SPV valve in accelerated wear tests.

CONCLUSIONS: These in vitro studies show that a tissue aortic valve designed on the basis of the proved engineering principle that form follows function has better hemodynamics, flow dynamics, stress distribution, and durability when compared under identical in vitro conditions with an excellent commercially available tissue aortic valve.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
S. Martens, A. Ploss, S. Sirat, A. Miskovic, A. Moritz, and M. Doss
Sutureless Aortic Valve Replacement With the 3f Enable Aortic Bioprosthesis.
Ann. Thorac. Surg., June 1, 2009; 87(6): 1914 - 1917.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
W. A. Goetz, T. E. Tan, K. H. Lim, S. L. H. Salgues, N. Grousson, F. Xiong, Y. L. Chua, and J. H. Yeo
Truly stentless molded autologous pericardial aortic valve prosthesis with single point attached commissures in a sheep model
Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 548 - 553.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
J. L. Cox and R.C. Quijano
Tubular heart valves
J. Thorac. Cardiovasc. Surg., March 1, 2007; 133(3): 845 - 846.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
B. Biancucci
Tubular heart valves
J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1419 - 1419.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The American Association for Thoracic Surgery.